Sijaka: Herbal Supplement for Antidiabetic and Antioxidants
Sijaka: Herbal Supplement for Antidiabetic and Antioxidants
Innovator: Prof. Mega Safithri
Purpose:
Sijaka (a blend of Red Betel, Red Ginger, and Cinnamon) is an anti-diabetes and antioxidant herbal supplement that helps maintain the body’s redox system balance. This product works by repairing pancreatic beta cells damaged by free radicals, inhibiting glucose absorption in the intestines, and suppressing free radicals and inflammation caused by high glucose levels.
Advantages:
-
Made from authentic Indonesian herbs: red betel, red ginger, and cinnamon.
-
Focused on supporting holistic body recovery, not just addressing symptoms.
-
Has been tested at the internationally ISO-accredited Saraswanti Indo Genetech (SIG) Laboratory.
-
Produced by PT Nano Herbaltama Indonesia with an official license.
-
Received research funding since 2005 and won several awards in 2012, 2016, and 2019.
-
Received positive testimonials from limited trials, although not yet officially commercialized.
-
Proof of IPB University’s excellence in biopharmaceutical research, particularly in anti-diabetes.
-
Supports Indonesia’s pharmaceutical independence by reducing reliance on imported drugs.
Description:
Prof. Mega Safithri, has been researching Indonesian herbal-based biopharmaceuticals since 2005. One of her flagship research results is Sijaka, a supplement made from red betel, red ginger, and cinnamon. This product has undergone testing in an international standard laboratory and is produced by PT Nano Herbaltama Indonesia.
“This is one proof that IPB University excels in biopharmaceutical research, especially for anti-diabetes,” explained Prof. Mega.
According to her, biopharmaceuticals play a major role in the health system because they can maintain the body’s oxidative stress balance, unlike synthetic chemical drugs that only address disease symptoms.
IPB University also partners with various industries such as PT Nano Herbaltama Indonesia, PT Nanotech Natura, and PT SOHO Industri Farmasi. Prof. Mega hopes that IPB University’s biopharmaceutical research will be further strengthened with clinical trials from the Faculty of Medicine, so that more innovations can be commercialized for the wider public.
